

MPN Advocacy & Education International
and
The MPN Alliance Australia
Present



**An International MPN Patient/Caregiver
Education Program**

Friday 28th April, 2017
Melbourne, Victoria



MPN Advocacy & Education International

Ann Brazeau, CEO

MPN Advocacy and Education International provides educational programs, materials, and resources for patients, caregivers, physicians, and entire healthcare teams to improve their understanding of myelofibrosis, polycythemia vera, and essential thrombocythemia. They are dedicated to making a difference in the lives of those affected by MPNs and strive to grow awareness and advocate on behalf of the MPN community. MPN Advocacy & Education International fosters collaboration with all entities who make a contribution to the MPN community through research, drug development, education and support.

MPN Advocacy and Education International brings you the most up to date information about MPN research, treatment options, clinical trials and available support that will empower and guide you through the course of your care or the care of loved ones.

Our speakers are experts in the field of MPN treatment and research, and many are directly involved in clinical trial studies. Other speakers are from the MPN community and share their insights and stories to shed light on living with a rare disease.

MPN Alliance Australia

The Myeloproliferative Neoplasms Alliance Australia (MPN AA) was formed in 2015 by a small group of motivated patients who themselves had a diagnosis of MPN. The patient-led advocacy group collaborates with the Leukaemia Foundation of Australia with the common goal of achieving better outcomes for Australian Patients. We aim to increase awareness and understanding of the MPNs and the plight of patients. Unifying the Australian MPN community by sharing information and vital links to existing resources, organisations and support, will be beneficial to newly diagnosed and existing patients and their families.

MPN patient quality of life is central to everything we do. Together, we strive to advocate for access to emerging treatments as well as contribute toward research to aid in the search for a cure.



Agenda

Friday 28th April

Morning Session

- 7:30 - 8:30 ` Registration
 Continental Breakfast will be served
- 8:30 - 9:00 Welcome/Opening Remarks
- MPN Advocacy & Education Int'l
 MPN Alliance Australia
- Welcome to Country from Aunty Diane
 Aboriginal Elder from the Wurundjeri Tribe*
- 9:00 - 9:30 Dr David Ross
 Diagnosing MPNs in 2017
- 9:30 - 10:00 Dr Kate Burbury
 Risk and Disease Burden in MPNs
- 10:00 - 10:15 Morning Break
- 10:15 - 10:45 Professor Wendy Erber
 Looking Inside the Bone Marrow of MPN
- 10:45 - 11:15 Dr Raajit Rampal, MD, PhD
 Interferon and New MPN Therapies
- 11:15 - 11:45 Patient Story
 Q & A
 Morning Wrap Up
- Noon Lunch Break

Friday 28th April



MPN Alliance Australia
Empower • Enrich • Entiven

Afternoon Session

- 13:00 - 13:30 Dr Ruben Mesa, MD
***Myelofibrosis and Advancing MPNs:
Current and Future Approaches***
- 13:30 - 14:00 Professor Andrew Grigg
MPN Patient Case Studies
- 14:00 - 14:30 Dr Cecily Forsyth
Lifestyle Changes Following an MPN Diagnosis
- 14:30 - 14:45 Afternoon Break
- 14:45 - 15:15 Dr Steven Lane
New Drugs for MPNs Evolving in AML
- 15:15 - 15:30 Dr Laura Michaelis, MD
MPNs in 2017-Medical Goals & Outcomes
- 15:30 - 16:30 Patient Breakouts-MF/PV/ET-Physician Rotation
- 15:30 - 16:30 Caregiver Breakout-Coping with your Role as Caregiver
- 16:30 Closing Remarks/Conclusion
- 17:00 Mix and Mingle Reception

MPN Expert Presenters



Dr David M. Ross, MBBS, PhD, FRACP, FRCPA
SA Pathology, South Australia

Dr. Ross is a consultant haematologist in SA Pathology with clinical appointments at the Royal Adelaide Hospital and Flinders Medical Centre in Adelaide, Australia. His PhD was on the topic of minimal residual disease and treatment-free remission in chronic myeloid leukaemia (CML). He has been an investigator in numerous clinical trials, including the landmark COMFORT-1 study of ruxolitinib in myelofibrosis. He supervises the diagnostic haematology service in SA Pathology and is an examiner for the Royal College of Pathologists of Australasia. His clinical and research interests include CML and Ph-negative myeloproliferative neoplasms. He is a Senior Research Fellow in the South Australian Health & Medical Research Institute.



Dr Kate Burbury MBBS(Hons) FRACP FRCPA DPhil
Peter MacCallum Cancer Centre, Vicotria

Dr Burbury is a consultant haematologist; stream lead for myeloproliferative disorders (MPD)/chronic myeloid leukaemia (CML) and lead clinician for haemostasis, thrombosis and peri-operative optimisation, including pre-habilitation, for all major cancer surgery patients at the VCCC. Kate is a member of professional societies, scientific committees, council member for Haematology Society for Australia and New Zealand, and actively involved in the development of expert guidelines and governance structures for both the institution and external working parties, including European Leukaemia Network: flow cytometry in myelodysplastic syndromes (MDS).



Professor Wendy Erber, FRCPA, FRCPATH, FAHMS
The University of Western Australia

Professor Erber graduated in Medicine with 1st class honours from the University of Sydney. She undertook her Haematology training at the Royal North Shore Hospital of Sydney and the University of Oxford as a Rhodes Scholar. In Oxford her research led to Doctorate of Philosophy. She has held Consultant Haematologist posts in Western Australia and in Cambridge, UK. From Cambridge she returned to Australia in 2011 to take up the appointment as Chair and Head of the School of Pathology and Laboratory Medicine at the University of Western Australia. In December 2016 she was appointed Pro Vice-Chancellor and Executive Dean of the Faculty of Health and Medical Sciences. Professor Erber continues to be active in diagnostic and translational research in haematology. Throughout her professional career Professor Erber's major interests have been the adoption of new cutting-edge technologies, translating discoveries to improved diagnostic pathology practice and hence better management for patients, especially in the field of haematological malignancies. She has more than 150 publications in peer-reviewed journals and publis



Dr Raajit Rampal, MD, PhD
Memorial Sloan Kettering, NYC

Dr. Rampal is a hematology-oncology physician who specializes in the treatment of leukemia and myeloproliferative neoplasms. He is an active researcher whose focus is the development of new and innovative approaches to treating MPNs and leukemia. He is working to understand the genetic events that contribute to the development and progression of leukemia and MPDs in the hope of developing new targeted therapies for patients with these diseases. Dr. Rampal received his medical degree in Molecular and Cellular Biology from Stony Brook University School of Medicine.

MPN Expert Presenters



Dr Ruben Mesa, MD

Mayo Clinic, Arizona

Dr. Mesa is Professor of Medicine, Director of the Acute and Chronic Leukemias Program in the Division of Hematology-Oncology at the Mayo Clinic in Arizona. He is committed to improving therapies and quality of life for patients with myeloproliferative neoplasms, including polycythemia vera, essential thrombocythemia and myelofibrosis. Dr. Mesa has been very active in evaluating new medicines focusing on targeted small molecules aimed at key aspects of the diseases, such as inhibiting known mutations, including JAK2; the fibrosing process in myelofibrosis; or symptomatic burdens, including anemia, splenomegaly or constitutional symptoms. He received his medical degree from the Mayo Medical School, Mayo Clinic College of Medicine.

Professor Andrew Grigg

Austin Hospital, Victoria



Professor Grigg has been the Director of Clinical Haematology at the Austin Hospital since 2010, after working for 19 years at Royal Melbourne Hospital. His main interests are in the management of patients and clinical research across a broad spectrum of haematological disorders, both benign and malignant. He has been involved as an investigator in a number of national studies in AML, non-Hodgkin lymphoma, CML, ET and ALL and published a number of manuscripts relating to the management of various myeloproliferative disorders.

Dr Cecily Forsyth MBBS FRACP FRCPA

Jarrett Street Specialist Centre, NSW



Dr Forsyth has worked as a clinical haematologist on the Central Coast of NSW for 20 years after training in haematology at Royal Prince Alfred Hospital. She is passionate about improving rural and regional patients' access to disease information, education and clinical trials, and providing educational opportunities for haematology trainees and haematology nurses. Her main clinical and research interest is myeloproliferative neoplasms and she has collaborated on Australian and International studies in these disorders. She is a member of the ALLG CML and MPN Disease Group Committee and has established the Myeloproliferative Neoplasms Registry (MPN01) on behalf of the ALLG.

Associate Professor Steven Lane, MBBS, PhD, FRACP, FRCPA

Royal Brisbane and Women's Hospital, QLD



Associate Professor Lane is a clinical haematologist interested in all aspects of benign and malignant haematology, with a particular focus on myeloid disorders such as acute myeloid leukaemia, myelodysplasia and myeloproliferative neoplasms. He achieved his medical degree from the University of Queensland and subsequently completed his clinical training at the Royal Brisbane and Women's Hospital and Princess Alexandra Hospital. His lab concentrates on basic science research to discover new treatments for myeloid disorders such as myeloproliferative neoplasm and acute myeloid leukaemia. He has received numerous awards recognising this research including the inaugural 2017 CSL Centenary Fellowship and funding from the NHMRC, Cure Cancer Australia and previously, from the leukaemia foundation.

and progression of leukemia and MPDs in the hope of developing new targeted therapies for patients with these diseases.

Dr. Laura Michaelis, MD

Medical College of Wisconsin/Froedtert Hospital



Dr. Michaelis is Associate Professor of Medicine at the Medical College of Wisconsin, Division of Hematology and Oncology, specializing in acute and chronic leukemias, myelodysplastic syndromes, myeloproliferative neoplasms, bone marrow failure syndromes, and myeloid disorders. Dr. Michaelis received her medical degree from Harvard Medical School.

MPN Advocacy & Education International Organizational Partners

MPN Alliance Australia
MPN Education Foundation
MPN Research Foundation
MPN Forum
Cancer Support Community
Cancer Research and Treatment Fund
National Organization for Rare Disorders (NORD)
Patient Access Network Foundation (PAN Foundation)
Leukemia Lymphoma Society
CancerCare
AA MDS International Foundation
BMT Infonet.org
MDS Foundation
Friends of ET Research

MPN Alliance Australia Organizational Partner

Leukaemia Foundation of Australia

For Additional Information Please Visit Our Websites

www.mpnadvocacy.com

www.leukaemia.org.au/mpn-alliance-australia